Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients with Early and Locally Advanced HER2-Positive Breast Cancer

    Summary
    EudraCT number
    		 2013-001161-16
    Trial protocol
    		 IT  
    Global end of trial date
    27 Mar 2018

    Results information
    Results version number
    		 v4(current)
    This version publication date
    31 Oct 2020
    First version publication date
    28 May 2017
    Other versions
    		 v1 , v2 , v3
    Version creation reason

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    ML28879
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01940497
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    F. Hoffmann-La Roche, Ltd.
    Sponsor organisation address
    Grenzacherstrasse 124, Basel, Switzerland, 4070
    Public contact
    Roche Trial Information Hotline, F. Hoffmann-La Roche, Ltd., +41 616878333, global.trial_information@roche.com
    Scientific contact
    Roche Trial Information Hotline, F. Hoffmann-La Roche, Ltd., +41 616878333, global.trial_information@roche.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    27 Mar 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    05 Apr 2016
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Mar 2018
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study was to assess the safety and tolerability of trastuzumab solution injected subcutaneously (vial or single-use injection device [SID]) in participants with human epidermal growth factor receptor 2 (HER2)-positive early or locally-advanced breast cancer.
    Protection of trial subjects
    The study was conducted in accordance with the principles of the “Declaration of Helsinki” and Good Clinical Practice (GCP) according to the regulations and procedures.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    07 Nov 2013
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    		 Safety
    Long term follow-up duration
    		 24 Months
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Italy: 240
    Worldwide total number of subjects
    240
    EEA total number of subjects
    240
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    197
    From 65 to 84 years
    43
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 Out of 263 screened participants, 240 participants were enrolled in the study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Trastuzumab (Vial)
    Arm description
    		 Participants received trastuzumab 600 milligrams (mg) subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
    Arm type
    		 Experimental

    Investigational medicinal product name
    Trastuzumab
    Investigational medicinal product code
    Other name
    Herceptin
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received trastuzumab 600 mg subcutaneously every 3 weeks (1 cycle) for 18 cycles.

    Arm title
    		 Trastuzumab (SID)
    Arm description
    		 Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
    Arm type
    		 Experimental

    Investigational medicinal product name
    Trastuzumab
    Investigational medicinal product code
    Other name
    Herceptin
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Participants received trastuzumab 600 mg subcutaneously every 3 weeks (1 cycle) for 18 cycles.

    Number of subjects in period 1
    		Trastuzumab (Vial) Trastuzumab (SID)
    Started
    121
    119
    Treated
    115
    113
    Completed
    100
    101
    Not completed
    21
    18
         Consent withdrawn by subject
    6
    2
         Refused Treatment
    1
    3
         Adverse Event/Intercurrent Illness
    11
    8
         Administrative/Other
    1
    1
         Violation of Entry Criteria
    1
    1
         Recurrence of Disease Postsurgery
    1
    3

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Trastuzumab (Vial)
    Reporting group description
    		 Participants received trastuzumab 600 milligrams (mg) subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Reporting group title
    Trastuzumab (SID)
    Reporting group description
    		 Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Reporting group values
    		 Trastuzumab (Vial) Trastuzumab (SID) Total
    Number of subjects
    		 121 119 240
    Age Categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 0 0 0
        Adults (18-64 years)
    		 94 103 197
        From 65-84 years
    		 27 16 43
        85 years and over
    		 0 0 0
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    		 55.1 ( 10.51 ) 53.2 ( 10.37 ) -
    Gender Categorical
    Units: Subjects
        Female
    		 120 119 239
        Male
    		 1 0 1

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Trastuzumab (Vial)
    Reporting group description
    		 Participants received trastuzumab 600 milligrams (mg) subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Reporting group title
    Trastuzumab (SID)
    Reporting group description
    		 Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (Vial): Adjuvant
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (Vial): Neoadjuvant
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (SID): Adjuvant
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (SID): Neoadjuvant
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (Vial): Adjuvant
    Subject analysis set type
    		 Modified intention-to-treat
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (Vial): Neoadjuvant
    Subject analysis set type
    		 Modified intention-to-treat
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (SID): Adjuvant
    Subject analysis set type
    		 Modified intention-to-treat
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    Trastuzumab (SID): Neoadjuvant
    Subject analysis set type
    		 Modified intention-to-treat
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Subject analysis set title
    HCPs: Trastuzumab (Vial)
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone). Trastuzumab using vial had to be administered by an HCP. Such HCPs were included in this group.

    Subject analysis set title
    HCPs: Trastuzumab (SID)
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone). Trastuzumab using SID had to be administered by an HCP or by the participant after appropriate training and under HCP supervision. Such HCPs were included in this group.

    Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    		 Close Top of page
    End point title
    		 Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) [1]
    End point description
    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neo-adjuvant chemotherapy groups within each treatment arm. Safety population included all enrolled participants who received at least one dose of study medication. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
    End point type
    Primary
    End point timeframe
    Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: This endpoint is descriptive only, there is no formal comparison between arms and statistical analysis
    End point values
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Adjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    95
    20
    92
    21
    Units: percentage of participants
        number (not applicable)
    98.9
    100.0
    89.1
    95.2
    No statistical analyses for this end point

    Secondary: Actual Dose of Trastuzumab Administered

    		 Close Top of page
    End point title
    		 Actual Dose of Trastuzumab Administered
    End point description
    Actual dose (mg) administered = (sum over all cycles of actual dose received [mg] divided by number of cycles). Safety population. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
    End point type
    Secondary
    End point timeframe
    Day 1 up last dose of trastuzumab (up to approximately 1 year)
    End point values
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Adjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    95
    20
    92
    21
    Units: mg
        arithmetic mean (standard deviation)
    599.7 ( 3.08 )
    600.00 ( 0.000 )
    593.3 ( 16.55 )
    595.9 ( 10.4 )
    No statistical analyses for this end point

    Secondary: Duration of Treatment with Trastuzumab

    		 Close Top of page
    End point title
    		 Duration of Treatment with Trastuzumab
    End point description
    Safety population. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
    End point type
    Secondary
    End point timeframe
    Day 1 up last dose of trastuzumab (up to approximately 1 year)
    End point values
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Adjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    95
    20
    92
    21
    Units: days
        arithmetic mean (standard deviation)
    346 ( 72.13 )
    352.2 ( 55.82 )
    340.1 ( 85.47 )
    351.9 ( 90.02 )
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Received Concomitant Medications

    		 Close Top of page
    End point title
    		 Percentage of Participants Who Received Concomitant Medications
    End point description
    Safety population.
    End point type
    Secondary
    End point timeframe
    Screening (Day -28 to -1) up to approximately 2.5 years
    End point values
    		 Trastuzumab (Vial) Trastuzumab (SID)
    Number of subjects analysed
    115
    113
    Units: percentage of participants
        number (not applicable)
    100
    100
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography

    		 Close Top of page
    End point title
    		 Percentage of Participants with Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography
    End point description
    In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Modified intent-to-treat (mITT) population included all enrolled participants satisfying criteria for eligibility. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm.
    End point type
    Secondary
    End point timeframe
    Day 1 up to 24 weeks
    End point values
    		 Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    22
    19
    Units: percentage of participants
        number (confidence interval 95%)
    40.9 (31.0 to 51.0)
    15.8 (8.00 to 24.0)
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography

    		 Close Top of page
    End point title
    		 Percentage of Participants with Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography
    End point description
    A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. m-ITT population. Here, ‘Number of Subjects Analysed’ = participants who were evaluable for this outcome measure. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
    End point type
    Secondary
    End point timeframe
    Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
    End point values
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Adjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    92
    18
    91
    18
    Units: percentage of participants
        number (not applicable)
    18.5
    33.3
    6.6
    11.1
    No statistical analyses for this end point

    Secondary: Disease-Free Survival (DFS) Using Mammography

    		 Close Top of page
    End point title
    		 Disease-Free Survival (DFS) Using Mammography
    End point description
    DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. m-ITT population. Here, ‘Number of Subjects Analysed’ = participants who were evaluable for this outcome measure. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. Here, '99999' indicates that median and corresponding 95% confidence interval (CI) could not be estimated because majority of participants were censored at data cut off date.
    End point type
    Secondary
    End point timeframe
    Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])
    End point values
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Adjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    92
    18
    91
    18
    Units: months
        median (confidence interval 95%)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    No statistical analyses for this end point

    Secondary: Percentage of Participants Who Died

    		 Close Top of page
    End point title
    		 Percentage of Participants Who Died
    End point description
    m-ITT population. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.
    End point type
    Secondary
    End point timeframe
    Day 1 up to death due to any cause (up to approximately 4.5 years)
    End point values
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Adjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    96
    22
    93
    19
    Units: percentage of participants
        number (not applicable)
    5.2
    4.5
    0.0
    5.26
    No statistical analyses for this end point

    Secondary: Overall Survival (OS)

    		 Close Top of page
    End point title
    		 Overall Survival (OS)
    End point description
    Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. m-ITT population. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. Here, '99999' indicates that median and corresponding 95% CI could not be estimated because majority of participants were censored at data cut off date.
    End point type
    Secondary
    End point timeframe
    Day 1 up to death due to any cause (up to approximately 4.5 years)
    End point values
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID): Adjuvant Trastuzumab (SID): Neoadjuvant
    Number of subjects analysed
    96
    22
    93
    19
    Units: months
        median (confidence interval 95%)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    99999 (99999 to 99999)
    No statistical analyses for this end point

    Secondary: Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ)

    		 Close Top of page
    End point title
    		 Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ) [2]
    End point description
    Participants were asked following 5 questions:(1)“Following first injection given by physician/nurse and training on SID, I felt comfortable injecting it by myself”;(2)“ SID was convenient and easy to use”;(3)“I am confident giving myself injection in thigh with SID”;(4)“Taking all things into account, I find self-administration using SID satisfactory”;(5)“If given opportunity, I would choose to continue self-injection using SID at home”. Responses were recorded as:“Unknown”,“Strongly Disagree”,“Disagree”,“Unsure”,“Agree”,“Strongly Agree”.Percentage of participants providing responses was reported. PSQ population included all enrolled participants from SID group who were able to use SID and had completed a minimum 14 administrations subcutaneously using SID (at least 10 of which were self-administered). Here, ‘Number of Subjects Analysed’ = participants who were evaluable for this outcome measure.Data for this outcome measure were analyzed and reported only for SID arm.
    End point type
    Secondary
    End point timeframe
    After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)
    Notes
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Data were not reported for vial group as this endpoint was only applicable for SID arm.
    End point values
    		 Trastuzumab (SID)
    Number of subjects analysed
    15
    Units: percentage of participants
    number (not applicable)
        Comfortable: Unknown
    0
        Comfortable: Strongly Disagree
    0
        Comfortable: Disagree
    0
        Comfortable: Unsure
    6.7
        Comfortable: Agree
    40
        Comfortable: Strongly Agree
    53.3
        Convenient: Unknown
    0
        Convenient: Strongly Disagree
    0
        Convenient: Disagree
    0
        Convenient: Unsure
    6.7
        Convenient: Agree
    33.3
        Convenient: Strongly Agree
    60
        Confident: Unknown
    0
        Confident: Strongly Disagree
    0
        Confident: Disagree
    0
        Confident: Unsure
    6.7
        Confident: Agree
    40
        Confident: Strongly Agree
    53.3
        Satisfactory: Unknown
    0
        Satisfactory: Strongly Disagree
    0
        Satisfactory: Disagree
    0
        Satisfactory: Unsure
    6.7
        Satisfactory: Agree
    33.3
        Satisfactory: Strongly Agree
    60
        Would continue: Unknown
    0
        Would continue: Strongly Disagree
    0
        Would continue: Disagree
    13.3
        Would continue: Unsure
    6.7
        Would continue: Agree
    20
        Would continue: Strongly Agree
    60
    No statistical analyses for this end point

    Secondary: Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)

    		 Close Top of page
    End point title
    		 Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)
    End point description
    Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions. HCPQ population included all investigators and study nurses who completed the questionnaire at each site when at least 4 participants from their site had received at least 5 cycles of adjuvant study treatment. Here, '9999' indicates that data were not evaluable as the question applied only to vial group; and '999999' indicates that data were not evaluable as the question applied only to SID group.
    End point type
    Secondary
    End point timeframe
    After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)
    End point values
    		 HCPs: Trastuzumab (Vial) HCPs: Trastuzumab (SID)
    Number of subjects analysed
    121 [3]
    119 [4]
    Units: percentage of health care professionals
    number (not applicable)
        Specialization: Oncologist
    17.3
    16.0
        Specialization: Specialist nurse
    69.2
    76.0
        Specialization: Other
    11.5
    8.0
        Specialization: Missing
    1.9
    0.0
        Personally administered/supervised: Always
    40.4
    48.0
        Personally administered/supervised: Sometimes
    51.9
    48.0
        Personally administered/supervised: Never
    7.7
    4.0
        If ‘Never’, who administered: Specialist nurse
    7.7
    4.0
        Syringe prepared at: Pharmacy
    55.8
    9999
        Syringe prepared at: Oncology ward
    40.4
    9999
        Syringe prepared at: Missing
    3.8
    9999
        Time to fill syringe: less than (<) 5 minutes
    67.3
    9999
        Time to fill syringe: 6-10 minutes
    13.5
    9999
        Time to fill syringe: 11-15 minutes
    5.8
    9999
        Time to fill syringe: Unknown
    13.5
    9999
        Total time for vial administration: <3 minutes
    1.9
    9999
        Total time for vial administration: <5 minutes
    59.6
    9999
        Total time for vial administration: 6-15 minutes
    38.5
    9999
        Time to prepare SID: <5 minutes
    999999
    72.0
        Time to prepare SID: 6-10 minutes
    999999
    14.0
        Time to prepare SID: 11-15 minutes
    999999
    4.0
        Time to prepare SID: 16-20 minutes
    999999
    2.0
        Time to prepare SID: >20 minutes
    999999
    8.0
        Total time for SID administration: <3 minutes
    999999
    26.0
        Total time for SID administration: <5 minutes
    999999
    30.0
        Total time for SID administration: 6-15 minutes
    999999
    44.0
        Injection site: Irritation: A lot
    1.9
    4.0
        Injection site: Irritation: A few
    46.2
    36.0
        Injection site: Irritation: None
    51.9
    60.0
        Injection site: Bruising: A few
    7.7
    10.0
        Injection site: Bruising: None
    92.3
    90.0
        Injection site: Infection: None
    100.0
    100.0
        Fever,shivering,flu-like,rash,swelling:A few
    15.4
    14.0
        Fever,shivering,flu-like,rash,swelling:None
    84.6
    86.0
        Time at hospital for administration: <2 hours
    44.2
    44.0
        Time at hospital for administration: >2, <3 hours
    23.1
    34.0
        Time at hospital for administration: >3, <4 hours
    23.1
    12.0
        Time at hospital for administration: >4 hours
    7.7
    10.0
        Time at hospital for administration: Missing
    1.9
    0.0
        Anxiety to participants: None
    82.7
    90.0
        Anxiety to participants: A fair amount
    17.3
    10.0
        Ease of vial administration: None
    5.8
    9999
        Ease of vial administration: A fair amount
    38.5
    9999
        Ease of vial administration: A lot
    55.8
    9999
        Subcutaneous route may simplify management: Yes
    94.2
    100.0
        Subcutaneous route may simplify management: No
    5.8
    0.0
        Would recommend SID to intravenous route: Yes
    96.2
    96.0
        Would recommend SID to intravenous route: No
    3.8
    4.0
        Would recommend subcutaneous route to medics: Yes
    100.0
    90.0
        Would recommend subcutaneous route to medics: No
    0.0
    8.0
        Would recommend subcutaneous to medics:Missing
    0.0
    2.0
        Convenience of using SID by participants: Yes
    94.2
    96.0
        Convenience of using SID by participants: No
    0.0
    4.0
        Convenience of using SID by participants: Yes/No
    5.8
    0.0
    Notes
    [3] - Total 52 health care professionals were analyzed.
    [4] - Total 50 health care professionals were analyzed.
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)
    Adverse event reporting additional description
    Safety population TEAEs
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    20.1
    Reporting groups
    Reporting group title
    Trastuzumab (Vial): Adjuvant
    Reporting group description
    		 Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Reporting group title
    Trastuzumab (Vial): Neoadjuvant
    Reporting group description
    		 Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Reporting group title
    Trastuzumab (SID) Adjuvant
    Reporting group description
    		 Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Reporting group title
    Trastuzumab (SID) Neoadjuvant
    Reporting group description
    		 Participants received trastuzumab 600 mg subcutaneously using SID every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).

    Serious adverse events
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID) Adjuvant Trastuzumab (SID) Neoadjuvant
    Total subjects affected by serious adverse events
         subjects affected / exposed
    5 / 95 (5.26%)
    3 / 20 (15.00%)
    7 / 92 (7.61%)
    2 / 21 (9.52%)
         number of deaths (all causes)
    5
    1
    0
    1
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Bladder transitional cell carcinoma
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intracranial tumour haemorrhage
         subjects affected / exposed
    1 / 95 (1.05%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Ovarian epithelial cancer metastatic
         subjects affected / exposed
    1 / 95 (1.05%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Adenocarcinoma pancreas
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Fibula fracture
         subjects affected / exposed
    1 / 95 (1.05%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tibia fracture
         subjects affected / exposed
    1 / 95 (1.05%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleuropericarditis
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Syncope
         subjects affected / exposed
    1 / 95 (1.05%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pryexia
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Anaphylactic shock
         subjects affected / exposed
    1 / 95 (1.05%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    1 / 21 (4.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Generalised anxiety disorder
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    0 / 95 (0.00%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Gastroenteritis
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Trastuzumab (Vial): Adjuvant Trastuzumab (Vial): Neoadjuvant Trastuzumab (SID) Adjuvant Trastuzumab (SID) Neoadjuvant
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    92 / 95 (96.84%)
    20 / 20 (100.00%)
    79 / 92 (85.87%)
    18 / 21 (85.71%)
    Vascular disorders
    Hot flush
         subjects affected / exposed
    7 / 95 (7.37%)
    5 / 20 (25.00%)
    7 / 92 (7.61%)
    2 / 21 (9.52%)
         occurrences all number
    7
    5
    7
    2
    Hypertension
         subjects affected / exposed
    7 / 95 (7.37%)
    5 / 20 (25.00%)
    8 / 92 (8.70%)
    1 / 21 (4.76%)
         occurrences all number
    7
    5
    8
    2
    Lymphoedema
         subjects affected / exposed
    5 / 95 (5.26%)
    1 / 20 (5.00%)
    1 / 92 (1.09%)
    1 / 21 (4.76%)
         occurrences all number
    5
    1
    1
    1
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    32 / 95 (33.68%)
    3 / 20 (15.00%)
    20 / 92 (21.74%)
    7 / 21 (33.33%)
         occurrences all number
    46
    9
    28
    8
    Pyrexia
         subjects affected / exposed
    18 / 95 (18.95%)
    4 / 20 (20.00%)
    13 / 92 (14.13%)
    4 / 21 (19.05%)
         occurrences all number
    31
    5
    15
    5
    Fatigue
         subjects affected / exposed
    12 / 95 (12.63%)
    0 / 20 (0.00%)
    12 / 92 (13.04%)
    1 / 21 (4.76%)
         occurrences all number
    18
    0
    21
    1
    Oedema peripheral
         subjects affected / exposed
    10 / 95 (10.53%)
    0 / 20 (0.00%)
    11 / 92 (11.96%)
    1 / 21 (4.76%)
         occurrences all number
    11
    0
    16
    1
    Mucosal inflammation
         subjects affected / exposed
    9 / 95 (9.47%)
    0 / 20 (0.00%)
    7 / 92 (7.61%)
    1 / 21 (4.76%)
         occurrences all number
    9
    0
    10
    1
    Chest pain
         subjects affected / exposed
    6 / 95 (6.32%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    1 / 21 (4.76%)
         occurrences all number
    6
    1
    0
    1
    Pain
         subjects affected / exposed
    7 / 95 (7.37%)
    0 / 20 (0.00%)
    3 / 92 (3.26%)
    1 / 21 (4.76%)
         occurrences all number
    8
    0
    3
    2
    Influenza like illness
         subjects affected / exposed
    5 / 95 (5.26%)
    1 / 20 (5.00%)
    2 / 92 (2.17%)
    1 / 21 (4.76%)
         occurrences all number
    5
    1
    2
    1
    Oedema
         subjects affected / exposed
    6 / 95 (6.32%)
    0 / 20 (0.00%)
    2 / 92 (2.17%)
    0 / 21 (0.00%)
         occurrences all number
    6
    0
    2
    0
    Injection site erythema
         subjects affected / exposed
    1 / 95 (1.05%)
    1 / 20 (5.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    1
    0
    Peripheral swelling
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    2 / 92 (2.17%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    2
    0
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    3 / 95 (3.16%)
    2 / 20 (10.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    3
    2
    0
    0
    Reproductive system and breast disorders
    Amenorrhoea
         subjects affected / exposed
    4 / 95 (4.21%)
    0 / 20 (0.00%)
    3 / 92 (3.26%)
    2 / 21 (9.52%)
         occurrences all number
    4
    0
    3
    2
    Menopausal symptoms
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    12 / 95 (12.63%)
    3 / 20 (15.00%)
    15 / 92 (16.30%)
    1 / 21 (4.76%)
         occurrences all number
    13
    3
    16
    2
    Epistaxis
         subjects affected / exposed
    14 / 95 (14.74%)
    0 / 20 (0.00%)
    8 / 92 (8.70%)
    2 / 21 (9.52%)
         occurrences all number
    18
    0
    8
    2
    Dyyspnoea
         subjects affected / exposed
    5 / 95 (5.26%)
    0 / 20 (0.00%)
    4 / 92 (4.35%)
    1 / 21 (4.76%)
         occurrences all number
    7
    0
    4
    1
    Oropharyngeal pain
         subjects affected / exposed
    3 / 95 (3.16%)
    1 / 20 (5.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences all number
    3
    2
    1
    0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    3 / 95 (3.16%)
    2 / 20 (10.00%)
    5 / 92 (5.43%)
    0 / 21 (0.00%)
         occurrences all number
    3
    2
    5
    0
    Panic attack
         subjects affected / exposed
    1 / 95 (1.05%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    0
    Investigations
    Ejection fraction decreased
         subjects affected / exposed
    13 / 95 (13.68%)
    2 / 20 (10.00%)
    3 / 92 (3.26%)
    3 / 21 (14.29%)
         occurrences all number
    13
    2
    3
    3
    Neutrophil count decreased
         subjects affected / exposed
    3 / 95 (3.16%)
    0 / 20 (0.00%)
    6 / 92 (6.52%)
    2 / 21 (9.52%)
         occurrences all number
    9
    0
    7
    3
    White blood cell count decreased
         subjects affected / exposed
    2 / 95 (2.11%)
    0 / 20 (0.00%)
    5 / 92 (5.43%)
    1 / 21 (4.76%)
         occurrences all number
    4
    0
    10
    1
    Alanine aminotransferase increased
         subjects affected / exposed
    3 / 95 (3.16%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    3 / 21 (14.29%)
         occurrences all number
    3
    0
    1
    5
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 95 (1.05%)
    0 / 20 (0.00%)
    0 / 92 (0.00%)
    2 / 21 (9.52%)
         occurrences all number
    1
    0
    0
    2
    Blood pressure increased
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Hepatic enzyme abnormal
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Hepatitis C virus test positive
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Transaminases increased
         subjects affected / exposed
    2 / 95 (2.11%)
    0 / 20 (0.00%)
    3 / 92 (3.26%)
    2 / 21 (9.52%)
         occurrences all number
    2
    0
    3
    2
    Injury, poisoning and procedural complications
    Radiation skin injury
         subjects affected / exposed
    1 / 95 (1.05%)
    2 / 20 (10.00%)
    2 / 92 (2.17%)
    0 / 21 (0.00%)
         occurrences all number
    1
    2
    2
    0
    Cardiac disorders
    Mitral valve incompetence
         subjects affected / exposed
    0 / 95 (0.00%)
    2 / 20 (10.00%)
    2 / 92 (2.17%)
    0 / 21 (0.00%)
         occurrences all number
    0
    2
    2
    0
    Tachycardia
         subjects affected / exposed
    6 / 95 (6.32%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    2 / 21 (9.52%)
         occurrences all number
    6
    0
    1
    4
    Nervous system disorders
    Paraesthesia
         subjects affected / exposed
    49 / 95 (51.58%)
    3 / 20 (15.00%)
    25 / 92 (27.17%)
    3 / 21 (14.29%)
         occurrences all number
    75
    3
    30
    4
    Headache
         subjects affected / exposed
    6 / 95 (6.32%)
    2 / 20 (10.00%)
    4 / 92 (4.35%)
    1 / 21 (4.76%)
         occurrences all number
    6
    3
    4
    1
    Dysgeusia
         subjects affected / exposed
    6 / 95 (6.32%)
    0 / 20 (0.00%)
    6 / 92 (6.52%)
    1 / 21 (4.76%)
         occurrences all number
    6
    0
    6
    1
    Neurotoxicity
         subjects affected / exposed
    3 / 95 (3.16%)
    3 / 20 (15.00%)
    5 / 92 (5.43%)
    1 / 21 (4.76%)
         occurrences all number
    6
    4
    5
    1
    Dizziness
         subjects affected / exposed
    5 / 95 (5.26%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    1 / 21 (4.76%)
         occurrences all number
    6
    0
    1
    1
    Neuropathy peripheral
         subjects affected / exposed
    5 / 95 (5.26%)
    0 / 20 (0.00%)
    2 / 92 (2.17%)
    1 / 21 (4.76%)
         occurrences all number
    6
    0
    2
    1
    Peripheral sensory neuropathy
         subjects affected / exposed
    1 / 95 (1.05%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    0
    Presyncope
         subjects affected / exposed
    2 / 95 (2.11%)
    1 / 20 (5.00%)
    1 / 92 (1.09%)
    1 / 21 (4.76%)
         occurrences all number
    2
    1
    2
    1
    Sciatica
         subjects affected / exposed
    5 / 95 (5.26%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences all number
    7
    0
    1
    0
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    20 / 95 (21.05%)
    4 / 20 (20.00%)
    4 / 92 (4.35%)
    0 / 21 (0.00%)
         occurrences all number
    31
    7
    4
    0
    Anaemia
         subjects affected / exposed
    15 / 95 (15.79%)
    2 / 20 (10.00%)
    7 / 92 (7.61%)
    4 / 21 (19.05%)
         occurrences all number
    16
    3
    8
    4
    Leukopenia
         subjects affected / exposed
    10 / 95 (10.53%)
    3 / 20 (15.00%)
    5 / 92 (5.43%)
    1 / 21 (4.76%)
         occurrences all number
    16
    3
    6
    1
    Eye disorders
    Eye disorder
         subjects affected / exposed
    1 / 95 (1.05%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    1
    1
    0
    0
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    25 / 95 (26.32%)
    3 / 20 (15.00%)
    15 / 92 (16.30%)
    6 / 21 (28.57%)
         occurrences all number
    48
    3
    17
    6
    Nausea
         subjects affected / exposed
    8 / 95 (8.42%)
    2 / 20 (10.00%)
    13 / 92 (14.13%)
    3 / 21 (14.29%)
         occurrences all number
    16
    3
    16
    3
    Stomatitis
         subjects affected / exposed
    6 / 95 (6.32%)
    3 / 20 (15.00%)
    7 / 92 (7.61%)
    3 / 21 (14.29%)
         occurrences all number
    7
    5
    7
    4
    Abdominal pain upper
         subjects affected / exposed
    8 / 95 (8.42%)
    1 / 20 (5.00%)
    5 / 92 (5.43%)
    0 / 21 (0.00%)
         occurrences all number
    9
    1
    5
    0
    Constipation
         subjects affected / exposed
    8 / 95 (8.42%)
    0 / 20 (0.00%)
    7 / 92 (7.61%)
    0 / 21 (0.00%)
         occurrences all number
    10
    0
    7
    0
    Vomiting
         subjects affected / exposed
    7 / 95 (7.37%)
    0 / 20 (0.00%)
    5 / 92 (5.43%)
    2 / 21 (9.52%)
         occurrences all number
    7
    0
    6
    3
    Abdominal pain
         subjects affected / exposed
    6 / 95 (6.32%)
    0 / 20 (0.00%)
    3 / 92 (3.26%)
    0 / 21 (0.00%)
         occurrences all number
    7
    0
    3
    0
    Dyspepsia
         subjects affected / exposed
    6 / 95 (6.32%)
    0 / 20 (0.00%)
    4 / 92 (4.35%)
    0 / 21 (0.00%)
         occurrences all number
    10
    0
    4
    0
    Haemorrhoids
         subjects affected / exposed
    2 / 95 (2.11%)
    0 / 20 (0.00%)
    5 / 92 (5.43%)
    0 / 21 (0.00%)
         occurrences all number
    2
    0
    6
    0
    Skin and subcutaneous tissue disorders
    Erythema
         subjects affected / exposed
    23 / 95 (24.21%)
    2 / 20 (10.00%)
    14 / 92 (15.22%)
    2 / 21 (9.52%)
         occurrences all number
    28
    2
    15
    2
    Nail disorder
         subjects affected / exposed
    11 / 95 (11.58%)
    2 / 20 (10.00%)
    9 / 92 (9.78%)
    0 / 21 (0.00%)
         occurrences all number
    11
    2
    9
    0
    Nail ridging
         subjects affected / exposed
    7 / 95 (7.37%)
    0 / 20 (0.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences all number
    7
    0
    1
    0
    Pruritus
         subjects affected / exposed
    7 / 95 (7.37%)
    0 / 20 (0.00%)
    6 / 92 (6.52%)
    1 / 21 (4.76%)
         occurrences all number
    7
    0
    6
    1
    Rash
         subjects affected / exposed
    4 / 95 (4.21%)
    2 / 20 (10.00%)
    7 / 92 (7.61%)
    0 / 21 (0.00%)
         occurrences all number
    4
    2
    8
    0
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Skin disorder
         subjects affected / exposed
    1 / 95 (1.05%)
    2 / 20 (10.00%)
    2 / 92 (2.17%)
    0 / 21 (0.00%)
         occurrences all number
    1
    2
    2
    0
    Renal and urinary disorders
    Dysuria
         subjects affected / exposed
    3 / 95 (3.16%)
    1 / 20 (5.00%)
    4 / 92 (4.35%)
    0 / 21 (0.00%)
         occurrences all number
    3
    1
    4
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    29 / 95 (30.53%)
    4 / 20 (20.00%)
    28 / 92 (30.43%)
    5 / 21 (23.81%)
         occurrences all number
    36
    4
    31
    8
    Myalgia
         subjects affected / exposed
    13 / 95 (13.68%)
    0 / 20 (0.00%)
    8 / 92 (8.70%)
    2 / 21 (9.52%)
         occurrences all number
    14
    0
    12
    2
    Back Pain
         subjects affected / exposed
    9 / 95 (9.47%)
    2 / 20 (10.00%)
    6 / 92 (6.52%)
    1 / 21 (4.76%)
         occurrences all number
    9
    3
    7
    1
    Pain in extremity
         subjects affected / exposed
    9 / 95 (9.47%)
    0 / 20 (0.00%)
    4 / 92 (4.35%)
    0 / 21 (0.00%)
         occurrences all number
    9
    0
    5
    0
    Musculoskeletal pain
         subjects affected / exposed
    6 / 95 (6.32%)
    1 / 20 (5.00%)
    8 / 92 (8.70%)
    1 / 21 (4.76%)
         occurrences all number
    8
    1
    8
    1
    Bone pain
         subjects affected / exposed
    4 / 95 (4.21%)
    0 / 20 (0.00%)
    5 / 92 (5.43%)
    0 / 21 (0.00%)
         occurrences all number
    8
    0
    7
    0
    Joint stiffness
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Osteopenia
         subjects affected / exposed
    3 / 95 (3.16%)
    1 / 20 (5.00%)
    2 / 92 (2.17%)
    0 / 21 (0.00%)
         occurrences all number
    3
    1
    2
    0
    Osteoporosis
         subjects affected / exposed
    5 / 95 (5.26%)
    0 / 20 (0.00%)
    3 / 92 (3.26%)
    0 / 21 (0.00%)
         occurrences all number
    5
    0
    3
    0
    Infections and infestations
    Cystitis
         subjects affected / exposed
    7 / 95 (7.37%)
    0 / 20 (0.00%)
    8 / 92 (8.70%)
    1 / 21 (4.76%)
         occurrences all number
    12
    0
    10
    1
    Influenza
         subjects affected / exposed
    3 / 95 (3.16%)
    1 / 20 (5.00%)
    9 / 92 (9.78%)
    3 / 21 (14.29%)
         occurrences all number
    3
    1
    10
    3
    Conjunctivitis
         subjects affected / exposed
    3 / 95 (3.16%)
    2 / 20 (10.00%)
    2 / 92 (2.17%)
    2 / 21 (9.52%)
         occurrences all number
    4
    2
    2
    2
    Mastitis
         subjects affected / exposed
    2 / 95 (2.11%)
    1 / 20 (5.00%)
    1 / 92 (1.09%)
    0 / 21 (0.00%)
         occurrences all number
    2
    2
    1
    0
    Pharyngitis
         subjects affected / exposed
    3 / 95 (3.16%)
    2 / 20 (10.00%)
    4 / 92 (4.35%)
    1 / 21 (4.76%)
         occurrences all number
    3
    2
    4
    1
    Postoperative wound infection
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    2 / 95 (2.11%)
    1 / 20 (5.00%)
    5 / 92 (5.43%)
    1 / 21 (4.76%)
         occurrences all number
    4
    1
    7
    1
    Hypophagia
         subjects affected / exposed
    0 / 95 (0.00%)
    1 / 20 (5.00%)
    0 / 92 (0.00%)
    0 / 21 (0.00%)
         occurrences all number
    0
    1
    0
    0

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    27 May 2014
    - Modifications were done in eligibility criteria. - For the purpose of fertility preservation (adjuvant participants only), luteinizing hormone-releasing hormone analogous administration was allowed without limitation. - Clarification was added on the time points for mammography, radiological examinations, and centralized analysis of tissue and blood samples at baseline, and on the process of left ventricular ejection fraction (LVEF) assessments. - An additional blood pressure assessment was included after study drug administration. - Allowed contraception was updated to align with exclusion criteria. - Timelines and procedures to assess breast cancer at screening was added to the Schedule of Assessments to align with the text in the protocol. - The lowest dose of docetaxel (75 milligrams per square meter [mg/m^2]) was to be permitted because it is routine medical practice.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:48:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA